NIH funds study of fully personalized immunotherapy AGS-004
Argos Therapeutics announced that the NIH Division of AIDS has approved $6.6 million in funding for an investigator-initiated Phase 2a adult eradication study of AGS-004, the company's investigational fully personalized immunotherapy for HIV. April 01, 2015